Two Approved Companion Diagnostics Validate Pembrolizumab Eligibility Across dMMR/MSI-H Tumors
Bridging studies confirm that the Ventana MMR RxDx Panel and FoundationOne CDx reliably identify dMMR/MSI-H tumor patients likely to respond ...
Bridging studies confirm that the Ventana MMR RxDx Panel and FoundationOne CDx reliably identify dMMR/MSI-H tumor patients likely to respond ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine